Bestselling author shares her No. 1 tip for raising mentally resilient kids: It's 'the single best thing you could do'
Your child is throwing a tantrum, and it's stressing you out.
Perhaps they're afraid of the dark, so you avoid an outburst by offering them a spot in your bed — but now it's a bad habit they can't seem to break. Or your child feels uncomfortable in social settings, so you let them stay home, and now they can't make friends at school.
Giving into your kids to avoid your own feelings of stress and anxiety does more harm than good in the long run, says bestselling author and personal growth expert Mel Robbins. It's a big mistake she made when raising her daughter, the 56-year-old said on a May 6 episode of "The Oprah Podcast."
"I really screwed this up as a mother," said Robbins. "As a mother, I take full responsibility for making my child's anxiety a hundred times worse. The single best thing you could do for your daughter is to get control of and heal your anxiety."Robbins herself was an anxious child, and her now-adult daughter expressed similar tendencies as a young kid, she said — sleeping on her mother's bedroom floor for almost a year due to separation anxiety, for example. Telling her "no" resulted in a fuss, triggering Robbins' own anxiety, so she allowed it to happen for longer than she should've, she added.
"You want to know what I taught my daughter by doing that? I taught her that you're not capable of facing something that's difficult," Robbins said. "She got to the point that she didn't want to go to school ... I couldn't leave and go anywhere."
Learning how to overcome your own anxiety is the first step to helping your kids do the same, said Robbins. And teaching them how to be mentally resilient gives them a better chance of becoming successful as adults, some psychologists say.
People may use several common-sense strategies to ward off stress: talking to a therapist or loved one, eating healthier and sleeping more, working out, writing in a journal. Other tactics may be less obvious, like sleeping with your phone in another room, Robbins noted.
"You're checking emails and messages [as soon as you wake up] and you wonder why you're stressed out and exhausted," said Robbins. "You're not even out of bed, and you have put all this other stuff in your brain."
Martha Beck, a Harvard University-trained sociologist, uses a process called KIST, or "kind internal self talk," she wrote for CNBC Make It in January.
Imagine your anxiety as a small, furry animal and tell it, "You're OK," or "Everything's fine." Then, when you feel even the smallest shift in your anxiety, "offer yourself kind wishes" — say something like, "May you feel peaceful," Beck wrote.
Finally, imagine tucking your anxiety into a cozy box and carrying it gently in a small bag slung over your shoulder, wrote Beck.
Once your emotions are in check, you can more effectively talk to your child. Robbins suggested some potential language to use: "I know this is scary, I know this feels uncomfortable and I'm going to be by your side. But you are capable of facing this, honey."
The calmer you are in your delivery, the more they'll believe it, Robbins said.
,
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
3 days ago
- CNBC
CEO of Sean Parker's breakthrough cancer drug institute on leading new race for cure
Karen Knudsen did not grow up in a scientifically centered home. She grew up in a military family. But at an early age, as a "naturally curious" kid, she came to love the experience of discovery and gravitated toward math and science. That led Knudsen to assume she would one day become a medical doctor. But her career went in another scientific direction, starting with a stint as a summer research intern working in the lab at the National Cancer Institute during the AIDS epidemic of the 1980s. "There was so much interest in trying to understand retrovirus like HIV, and so I went to a lab that was actually using retrovirus as a way to study cancer," she recalled in a recent interview with CNBC's Julia Boorstin for the CNBC Changemakers Spotlight series (Knudsen was named to the inaugural CNBC Changemakers list in 2024). "It got me very interested in that direct line. How does what I'm doing right now in the laboratory have an opportunity to impact a life, and I got hooked, and I never looked back," she said. Knudsen's experience as an oncology researcher at large health care systems, and seeing many mergers taking place around her, led to the realization that it might help to know more about the business of health care. She chose to pursue an MBA. "I'm not sure I'll forget the look on my husband when I came home one day and said, 'I'm going to get my MBA'," Knudsen recalled. "That was probably one of the more unexpected decisions." Ultimately, it led to Knudsen becoming the first female CEO of the more-than-century-old American Cancer Society, though she says it's even more important that she was the first CEO for the organization to come from oncology research. Under Knudsen's leadership, ACS's revenue increased by over 30%. Recently, Knudsen assumed the CEO post at the Parker Institute for Cancer Immunotherapy — created by Sean Parker, Facebook's first president and the tech entrepreneur behind breakthrough ideas like Napster — where a new philanthropy-meets-venture-capital business model that aligns with Knudsen's lifelong interest in discovery is being built. The mission hasn't changed: "In the U.S., we have 2.1 million Americans that are going to get a new cancer diagnosis this year, and unfortunately, 600,000 plus people who will die from one of the 200 diseases we call cancer," she said. While there has been a 34% decline in cancer mortality since 1991, primarily attributed to earlier detection and preventative health practices, Knudsen's new role places her at the forefront of efforts to fund a new generation of breakthrough cancer drugs. Knudsen spoke with CNBC's Boorstin about how she reached this stage of her career, and the lessons she has learned from a lifetime devoted to experimentation. Here are some highlights from the full video interview. As a scientist, Knudsen says, "You get very comfortable with hypothesis generation and testing," and that is in some ways similar to a business executive trying to figure out what is going to come next in their market, and how to remain successful as conditions change. Scientists get comfortable developing a set of success metrics that enable them to know quickly whether it's time to quit on a hypothesis or move ahead. Knudsen says that is part of the "overlapping mindset between being a scientist and being a business person" which has helped her to succeed as she moved from research into executive leadership. "It made the process of developing a set of success metrics and creating a business strategy that tells you when you may be onto something, or not, fairly easy," she said. As a researcher within health systems who saw firsthand how a wave of consolidation could reshape entities and raise the question of how every person, process and practice might need to change, Knudsen says you need to be ready to identify not only what works but also what needs to go away. Coming into the CEO post at ACS was "like coming into a fresh merger that was in need of business transformation," she said. "Finding opportunities and fixing what needs repairing is often the hardest part of leadership," she added. Knudsen took a hard look at a bureaucracy that over more than a century had grown into 12 separate organizations, with 12 CEOs and 12 strategies, and she made significant changes to streamline the operation. It wasn't all about rooting out the inefficiencies, though. "I was on the road 49 weeks of the year for four years in a row, because you really needed to be there to see what was so good in these various areas, and apply that to the rest of the organization," Knudsen said. Her larger point is that a lifetime in research has made her a leader who sees change as a constant. "Because medicine is changing, science is changing, technology will change ... It's okay to transform and to constantly iterate," she said. Sean Parker comes out of the Silicon Valley "move fast and break things" world of success, and Knudsen says she had learned to be "a little more confident at risk-taking" over the years. Working with Parker, who was the first president of Facebook and co-founder of Napster, is the culmination of the risk-taking business side of her mindset. "He's unafraid of thinking differently," Knudsen said, adding that he still embodies the idea that "if we're failing, let's fail fast." More specifically, she said Parker identified that lack of access to capital was a major impediment to progress in the fight against cancer, and that was holding the risk takers back from doing what they do best. "The whole philosophy of the Parker Institute is to, step one, collect the best brains. Give them investment in funding to do the high risk, high gain, cutting-edge research, which could fail but could also dramatically transform cancer therapy," she said. Founded in 2016 by Parker to turn all cancers into "curable diseases," the institute supports clinical testing, startup formation and incubation, and drug commercialization. In all, PICI has supported the work of 1,000 researchers and helped to create a $4 billion venture capital portfolio that includes 17 biotech companies. "I think it's because we've de-risked the science from the very beginning," Knudsen said. "We're not waiting for someone to pitch for us. So I'm feeling very bullish about the ability to crank this wheel," she said. Knudsen has had many mentors throughout her journey. One she cited was Nancy Brown, CEO of the American Heart Association, who she says was a "fountain of knowledge" to her. But as CEO of the American Cancer Society, she surrounded herself "with CEOs from all walks of life. I had a CEOs council that was hot dial," Knudsen said. "There are some things you just really need to talk to other CEOs about." She also emphasized that women pursuing success should expect to have to fight even harder for female representation the higher they ascend up a professional ladder. Statistically, that is the case whether in the business or academic world. More than 50% of both MD and PhD programs are filled with women, but only 12% become full professors, department chairs or deans. In the business world, 10% of women hold CEO positions in S&P 500 companies; and approximately 12% in VC-backed companies and 13% at health-care firms. The hurdles, whether it is related to gender, the inherent risk of failure in scientific endeavors, or lack of access to capital, are barriers that Knudsen's mission has helped her to overcome. "What I've always wanted to do, whether it's as a scientist, whether it's as a health executive, the CEO of the American Cancer Society or now the Parker Institute, it's to get innovation to people," she said. "We're at this moment in time where there is so much discovery that's happening, the pace of change is truly logarithmic, and yet, too many great ideas don't ever make it off the laboratory floor."
Yahoo
3 days ago
- Yahoo
Dr. James Y. Wang Joins Epicutis as Chairman of the Scientific Advisory Board
Harvard-Trained Dermatologist Brings Expertise to Biotech Skin Health Brand IRVINE, Calif., June 18, 2025 /PRNewswire/ -- Epicutis, a pioneering biotech skincare brand known for its science-backed, clean formulations that prioritize skin health over beauty, proudly announces the appointment of Dr. James Y. Wang as Chairman of its Scientific Advisory Board. As a Harvard and UCLA-trained double board-certified dermatologist and dermatopathologist, Dr. Wang brings a wealth of expertise in medical and aesthetic dermatology, reinforcing Epicutis' mission to deliver clinically advanced, non-toxic skincare solutions to market. James Y. Wang, MD, Founder of Metropolis Dermatology, with five locations in California, is widely recognized as a leader in dermatology, specializing in the diagnosis and treatment of skin cancers, psoriasis, eczema, and acne. His impressive academic background includes graduating summa cum laude and Phi Beta Kappa in biology from Washington University in St. Louis, followed by earning his MD from Harvard Medical School and an MBA in healthcare policy from Harvard Business School. "As a physician, I am committed to evidence-based skincare that is not only safe for all skin types but also effective," shares Dr. Wang. "Epicutis represents the perfect fusion of biotechnology and dermatological science, delivering formulations that truly transform skin health at a cellular level, and I am honored to contribute to this next chapter of innovation." Epicutis was founded on the principles of biotech-driven skincare, leveraging the research of Dr. Jeffrey Stock, a distinguished biophysicist and Princeton University professor. By harnessing proprietary, patented active ingredients, Epicutis formulates small-batch, high-performance skincare products available exclusively through skin professionals. With a focus on transparency, efficacy, and the elimination of unnecessary additives and stabilizers, the brand continues to set new standards in professional skincare. "We are thrilled to have Dr. Wang join us as Chairman of our Scientific Advisory Board," said Maxwell Stock, Founder and CEO of Epicutis. "His deep understanding of dermatological science and passion for cutting-edge innovation align perfectly with our mission to clean up the skincare industry and support clinicians with science-backed, 100% non-toxic products that make a true impact on skin health." With Dr. Wang's leadership, Epicutis is advancing its commitment to safe, biotech-driven skincare solutions while championing higher regulation to ensure safety and efficacy in an industry often dominated by misleading marketing and mass production. By prioritizing science-backed formulations with patented, highly concentrated therapeutic ingredients, Epicutis is empowering skincare professionals to stand a chance against big beauty. More than just providing innovative products – the brand is actively investing in its partners' success, helping aesthetic businesses grow with exclusive, clinical-grade solutions that drive real results and build lasting patient trust. For more information on Epicutis and its revolutionary approach to skincare, visit About EpicutisEpicutis is a science-based, luxury professional skincare line that treats skin health and not age. Honoring a commitment to clean beauty and fewer ingredients, Epicutis offers science-based skincare using patented active ingredients in small-batch formulations created by expert formulator Masanori Tamura. Epicutis' novel ingredients are developed in-house by a team of scientists at Signum Biosciences utilizing technology discovered by Dr. Jeffry Stock at Princeton University. Signum Biosciences is a biopharmaceutical company focused on the discovery and development of innovative products to address major consumer and medical needs, and the development of compounds and botanical extracts that are mimetics of natural lipid ligands crucial to cellular regulation and signaling. To learn more about Epicutis, visit To learn more about Signum Biosciences, visit View original content to download multimedia: SOURCE Epicutis Skincare Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
UPI
4 days ago
- UPI
Investors flock to Chinese herbal medicine stock with no revenues
Regencell Bioscience Holdings' NASDAQ stock price rallied with a 280% increase on Monday and another 25% on Tuesday after a recent 38-for-1 stock split took effect on Thursday. File Photo by Angelina Katsanis/UPI | License Photo June 17 (UPI) -- Shares in Hong Kong-based Regencell Bioscience Holdings nearly quadrupled in value amid a 38-to-1 stock split despite the firm reporting no revenues. The stock split triggered a 280% share price increase on Monday, CNBC reported, and continued a 58,000% increase in its price in 2025, with a closing cost of $78 per share on the NASDAQ trading platform on Tuesday. The stock reached a high of $81.23 during morning trading and slumped slightly to $75.47 during Tuesday's after-hours trading. The stock is rated as a "buy" on the TipRanks website after Regencell officials on June 2 announced the stock split to improve its liquidity and value for shareholders. The stock split gave investors 37 shares for each share held on June 12. The shares began trading on a split-adjusted basis on Monday, according to Seeking Alpha. The firm has no reported revenue but says it is developing a Chinese herbal treatment for childhood attention deficit hyperactivity disorder and autism. The firm was established in 2014 and has been traded on NASDAQ under the RGC symbol since 202. It had a market capitalization of $29.7 billion at the end of trading on Monday. The market capitalization rose another 25% on Tuesday, with a total value of $36 billion. The stock traded for pennies per share last year but now has a greater market value than highly recognized businesses, including Kraft Heinz, Lululemon and eBay, according to CNBC. Part of the increased investor interest is due to Health and Human Services Secretary Robert Kennedy Jr. raising awareness of alternative medicines. Regencell Chief Executive Officer Yat-Gai Au controls more than 86% of the company's outstanding shares, according to FactSet. Little information is available about the potential effectiveness of the company's claims regarding its three traditional Chinese medicine formulas that are supposed to treat mild to severe forms of ADHD and autism with natural herbal medications in liquid form. Company officials in October reported no generated revenue and no regulatory approvals for its three liquid medicines. They reported net losses of $6.06 million in 2023 and $4.36 million in 2024. A Regencell patient case study in late 2023 said 28 patients were treated over three months during a second trial, which showed improvements in ADHD and autism. A dozen patients participated in a 2021 study to treat COVID-19, which indicated improvement in their symptoms.
